We are live on ! Find out more
CFO

Callan Family Office Portfolio holdings

AUM $4.41B
1-Year Est. Return 26.21%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
+26.21%
3 Year Est. Return
+68.96%
5 Year Est. Return
10 Year Est. Return
AUM
$3.17B
AUM Growth
+$1.84B
Cap. Flow
+$1.59B
Cap. Flow %
50.05%
Top 10 Hldgs %
25.88%
Holding
941
New
398
Increased
483
Reduced
23
Closed
10

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$74.8M
2
NVDA icon
NVIDIA
NVDA
+$66.1M
3
AAPL icon
Apple
AAPL
+$49.9M
4
AMZN icon
Amazon
AMZN
+$46.4M
5
META icon
Meta Platforms (Facebook)
META
+$31.7M

Sector Composition

Rank Sector Weight
1 Technology 23.33%
2 Financials 14.81%
3 Healthcare 9.6%
4 Industrials 7.93%
5 Communication Services 7.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASML icon
51
ASML
ASML
$669B
$11.5M 0.36%
14,357
+9,579
+200% +$6.87M
SNY icon
52
Sanofi
SNY
$104B
$11.4M 0.36%
235,522
+163,920
+229% +$8.38M
MET icon
53
MetLife
MET
$62.1B
$11.4M 0.36%
141,146
+97,391
+223% +$7.52M
MDY icon
54
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27.3B
$11.3M 0.36%
19,875
-292
-1% -$157K
IWM icon
55
iShares Russell 2000 ETF
IWM
$83B
$11.1M 0.35%
51,610
-5,296
-9% -$1.07M
BNY
56
Bank of New York Mellon
BNY
$107B
$10.8M 0.34%
118,428
+82,132
+226% +$6.97M
NVS icon
57
Novartis
NVS
$297B
$10.5M 0.33%
87,048
+60,949
+234% +$6.87M
CI icon
58
Cigna
CI
$74.6B
$10.5M 0.33%
31,706
+22,179
+233% +$7.15M
ACN icon
59
Accenture
ACN
$108B
$10.2M 0.32%
34,109
+13,449
+65% +$4.1M
GILD icon
60
Gilead Sciences
GILD
$165B
$9.95M 0.31%
89,738
+63,300
+239% +$6.74M
VWO icon
61
Vanguard FTSE Emerging Markets ETF
VWO
$124B
$9.78M 0.31%
197,720
+5,259
+3% +$244K
CMCSA icon
62
Comcast
CMCSA
$90B
$9.71M 0.31%
272,073
+188,935
+227% +$6.54M
FDX icon
63
FedEx
FDX
$75.4B
$9.69M 0.31%
42,646
+28,867
+209% +$6.32M
PG icon
64
Procter & Gamble
PG
$339B
$9.65M 0.3%
60,592
+31,123
+106% +$5.08M
ORCL icon
65
Oracle
ORCL
$423B
$9.6M 0.3%
43,906
+21,247
+94% +$3.43M
CRWD icon
66
CrowdStrike
CRWD
$218B
$9.6M 0.3%
75,360
+50,028
+197% +$5.42M
CVX icon
67
Chevron
CVX
$366B
$9.29M 0.29%
64,898
+29,234
+82% +$4.12M
CSCO icon
68
Cisco
CSCO
$479B
$9.24M 0.29%
133,154
+80,358
+152% +$4.94M
PRI icon
69
Primerica
PRI
$9.89B
$9.15M 0.29%
33,447
+30,220
+936% +$8.01M
VXUS icon
70
Vanguard Total International Stock ETF
VXUS
$160B
$9.11M 0.29%
131,868
+9,283
+8% +$603K
KO icon
71
Coca-Cola
KO
$375B
$9.09M 0.29%
128,434
+79,824
+164% +$5.69M
APD icon
72
Air Products & Chemicals
APD
$67.6B
$8.98M 0.28%
31,830
+18,648
+141% +$5.1M
AMGN icon
73
Amgen
AMGN
$222B
$8.64M 0.27%
30,956
+16,247
+110% +$4.6M
VST icon
74
Vistra
VST
$47.4B
$8.64M 0.27%
44,593
+23,649
+113% +$3.5M
GSK icon
75
GSK
GSK
$106B
$8.58M 0.27%
223,419
+156,628
+235% +$5.98M

Similar funds

Callan Family Office's Q2 2025 Portfolio in Review

As of Q2 2025, Callan Family Office held 941 positions worth $3.17B, up 138% from $1.33B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Callan Family Office deployed $1.59B of net new capital in Q2 2025, opening 398 new positions and adding to 483 existing holdings. Its largest new stake was Fortive: 72,724 shares worth $3.79M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $1.79M trimmed.

  • Callan Family Office's largest Q2 2025 buy was Fortive: 72,724 shares worth $3.79M.
  • Callan Family Office added most to Microsoft in Q2 2025, an estimated $74.8M increase.
  • Callan Family Office's biggest Q2 2025 reduction was iShares Russell 1000 Value ETF, cutting an estimated $1.79M.
  • Callan Family Office fully exited Discover Financial Services in Q2 2025, selling an estimated $2.79M.
  • Callan Family Office's ten largest holdings make up 26% of its $3.17B portfolio in Q2 2025.
  • Callan Family Office opened 398 new positions and closed 10 in Q2 2025.
  • Callan Family Office's portfolio value rose 138% quarter-over-quarter to $3.17B.

Based on Callan Family Office's 13F filing for Q2 2025, filed 24 Jul 2025.